Journal of Clinical Oncology最新文献

筛选
英文 中文
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations. 国家癌症研究所生化复发前列腺癌工作组:临床试验设计考虑。
IF 45.3 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-23 DOI: 10.1200/jco-25-01693
David J Einstein,Melissa L Abel,Jeanny B Aragon-Ching,Philip M Arlen,Karen A Autio,Marijo Bilusic,Michael A Carducci,Peter L Choyke,Deborah E Citrin,William D Figg,Julie N Graff,James L Gulley,Susan Halabi,Fatima Karzai,Liza Lindenberg,Mark C Markowski,Catherine H Marshall,Douglas G McNeel,Esther Mena,Helen Moon,Russell K Pachynski,Channing J Paller,Krishnan R Patel,Edwin M Posadas,Kenneth J Pienta,Meredith M Regan,Laura A Sena,Charlotte S Walmsley,Xiao X Wei,Evan Y Yu,Phuoc T Tran,Ravi A Madan
{"title":"National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.","authors":"David J Einstein,Melissa L Abel,Jeanny B Aragon-Ching,Philip M Arlen,Karen A Autio,Marijo Bilusic,Michael A Carducci,Peter L Choyke,Deborah E Citrin,William D Figg,Julie N Graff,James L Gulley,Susan Halabi,Fatima Karzai,Liza Lindenberg,Mark C Markowski,Catherine H Marshall,Douglas G McNeel,Esther Mena,Helen Moon,Russell K Pachynski,Channing J Paller,Krishnan R Patel,Edwin M Posadas,Kenneth J Pienta,Meredith M Regan,Laura A Sena,Charlotte S Walmsley,Xiao X Wei,Evan Y Yu,Phuoc T Tran,Ravi A Madan","doi":"10.1200/jco-25-01693","DOIUrl":"https://doi.org/10.1200/jco-25-01693","url":null,"abstract":"PURPOSEBiochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research inspired by ultrasensitive next-generation imaging. Most phase III trials in PCa have focused on metastatic disease, defined by conventional imaging. Despite the emergence of new imaging, clinical trial principles from metastatic studies will not optimize future BCR trials.METHODSA Working Group convened at the National Cancer Institute on November 13, 2024 (NCI BCR WG). Key areas of discussion included nomenclature, baseline criteria for data capture, imaging considerations, delineation of high-risk populations to be targeted for trial development, requirements of metastasis-directed therapy (MDT) or hormonal therapy, quality-of-life considerations, and potential study end points.RESULTSThe NCI BCR WG defined the novel term \"prostate-specific membrane antigen (PSMA)+BCR\" to identify the emerging concept of recurrent PCa identifiable only on PSMA positron emission tomography (PET), overlapping with BCR and distinct from metastatic hormone-sensitive PCa as traditionally defined by conventional imaging. The WG suggested defining high-risk BCR with a prostate-specific antigen doubling time of ≤6 months, regardless of PET findings. The WG provided recommendations for baseline data capture and imaging requirements. Neither systemic therapy nor MDT were considered mandatory for control arms. The WG also discussed novel end points and quality-of-life metrics in this disease space.CONCLUSIONThese discussions should inform future clinical BCR trials in this distinct disease space relative to metastatic disease defined by conventional imaging. The NCI BCR WG strongly advocates that future trials explore deintensification of treatment to minimize toxicity in this relatively indolent disease state.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"101 1","pages":"JCO2501693"},"PeriodicalIF":45.3,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145351591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-Arm Pivotal Studies in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer. 卡介苗芽孢杆菌-谷氨酰胺-无反应性非肌肉侵袭性膀胱癌的单臂关键研究。
IF 45.3 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-21 DOI: 10.1200/jco-25-01893
Jathin Bandari,Edward M Messing
{"title":"Single-Arm Pivotal Studies in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.","authors":"Jathin Bandari,Edward M Messing","doi":"10.1200/jco-25-01893","DOIUrl":"https://doi.org/10.1200/jco-25-01893","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"78 1","pages":"JCO2501893"},"PeriodicalIF":45.3,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145338653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Utility of Geriatric Assessment and Management in Older Adults With Cancer: Model-Based Economic Evaluation. 老年癌症患者的老年评估和管理的成本-效用:基于模型的经济评估。
IF 45.3 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-21 DOI: 10.1200/jco-25-00248
Selai Akseer,Shant Torkom Yeretzian,Lusine Abrahamyan,Martine Puts,Mostafa Mohamed,Wee Kheng Soo,Shabbir M H Alibhai,Yeva Sahakyan
{"title":"Cost-Utility of Geriatric Assessment and Management in Older Adults With Cancer: Model-Based Economic Evaluation.","authors":"Selai Akseer,Shant Torkom Yeretzian,Lusine Abrahamyan,Martine Puts,Mostafa Mohamed,Wee Kheng Soo,Shabbir M H Alibhai,Yeva Sahakyan","doi":"10.1200/jco-25-00248","DOIUrl":"https://doi.org/10.1200/jco-25-00248","url":null,"abstract":"PURPOSEGeriatric assessment and management (GAM) is a guideline-recommended strategy for optimizing cancer management among older adults. A recent cost-utility analysis of the Canadian 5C randomized controlled trial (RCT) found GAM to be cost effective for selected groups. This study aimed to assess the cost-utility of GAM plus usual care (UC) versus UC alone in older adults with cancer using a decision model and best available evidence from four international RCTs-GAIN, GAP70, INTEGERATE, and 5C.METHODSFor the model, we used pooled data from four RCTs and peer-reviewed literature. Deterministic and probabilistic analyses were performed from the Canadian health care payer perspective, applying a 6-month time horizon. Sensitivity analyses included per-trial scenario analyses, 1-year time horizon, and US health care payer perspective. We reported costs per quality-adjusted life year (QALY) and incremental net monetary benefit (INMB).RESULTSThe base-case analysis indicated that GAM had an INMB of $599 in Canadian dollars (CAD; 95% credibility interval, -$3,428 to $4,742) with 60.9% probability of being cost effective at a threshold of $50,000 (CAD) per QALY. Trial-specific results varied, with the GAP70 and INTEGERATE trials yielding positive INMB ($2,231 [CAD] and $2,104 [CAD], respectively), suggesting cost-effectiveness, whereas 5C and GAIN resulted in negative INMB (-$489 [CAD] and -$234 [CAD], respectively). Chemotherapy and hospitalization costs were the main driver of costs in both strategies.CONCLUSIONGAM is overall cost effective, with results varying across trial scenarios due to differences in chemotherapy dose intensity, hospitalization rates, and associated costs. Future research should prioritize identifying optimal core GAM components, delivery mode, and patient selection criteria to enhance its effectiveness and cost-effectiveness.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"39 1","pages":"JCO2500248"},"PeriodicalIF":45.3,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145338654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to: "Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer" and "CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer". 回复:“对低雌激素受体乳腺癌治疗重点的再思考”和“低雌激素受体乳腺癌CDK4/6抑制剂”
IF 41.9 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-20 Epub Date: 2025-08-28 DOI: 10.1200/JCO-25-01688
Matthew P Goetz, Grace M Choong, Tanya L Hoskin, Judy C Boughey, Sameera R Wijayawardana, James N Ingle
{"title":"Reply to: \"Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer\" and \"CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer\".","authors":"Matthew P Goetz, Grace M Choong, Tanya L Hoskin, Judy C Boughey, Sameera R Wijayawardana, James N Ingle","doi":"10.1200/JCO-25-01688","DOIUrl":"10.1200/JCO-25-01688","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3323-3324"},"PeriodicalIF":41.9,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer. 新型系统抗癌治疗和健康服务在成年癌症患者生命末期的使用。
IF 41.9 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-20 Epub Date: 2025-06-04 DOI: 10.1200/JCO-24-02816
Javaid Iqbal, Rahim Moineddin, Kieran L Quinn, Christopher M Booth, Craig C Earle, Stephanie Lheureux, Robert Grant, Jenny Lau, Lisa W Le, Peter Tanuseputro, James Downar, Gary Rodin, Hsien Seow, Jillian Tsai, Robert A Fowler, Breffni Hannon, Monika K Krzyzanowska, Camilla Zimmermann
{"title":"Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer.","authors":"Javaid Iqbal, Rahim Moineddin, Kieran L Quinn, Christopher M Booth, Craig C Earle, Stephanie Lheureux, Robert Grant, Jenny Lau, Lisa W Le, Peter Tanuseputro, James Downar, Gary Rodin, Hsien Seow, Jillian Tsai, Robert A Fowler, Breffni Hannon, Monika K Krzyzanowska, Camilla Zimmermann","doi":"10.1200/JCO-24-02816","DOIUrl":"10.1200/JCO-24-02816","url":null,"abstract":"<p><strong>Purpose: </strong>Use of chemotherapy at the end of life (EOL) is discouraged, but evidence to guide decisions on the use of novel systemic anticancer treatment (SACT) agents is lacking. We examined trends of use among SACT types and association with health services use at the EOL.</p><p><strong>Materials and methods: </strong>We analyzed Canadian Ontario Cancer Registry data for adults diagnosed with solid tumors or hematologic malignancies within 5 years of death who received SACT between March 2015 and March 2021. Receipt of SACT in the last 30 days of life was categorized as chemotherapy alone, chemotherapy and immunotherapy, immunotherapy alone, and targeted therapy alone. Outcomes included high health services use, including multiple (≥2) emergency department (ED) visits, multiple (≥2) hospitalizations, or any (≥1) intensive care unit admission, and hospital deaths. Segmented linear regression estimated monthly trends; multivariable logistic regression estimated adjusted odds ratios (aORs) of outcomes for various SACT types.</p><p><strong>Results: </strong>Among 68,963 patients, 18,337 (26.6%) received SACT at the EOL. From March 2015 to March 2020, use of SACT at the EOL increased (0.072% per month; <i>P</i> < .001), mainly driven by increased use of immunotherapy alone (0.064% per month; <i>P</i> < .001). Adjusted odds of high health services use and hospital death were more than two-fold greater among patients receiving SACT at the EOL (vs. none); individual aORs of high health services use and hospital death were 2.20 and 2.72 for chemotherapy alone, 2.36 and 3.10 for chemotherapy and immunotherapy, 1.92 and 2.27 for immunotherapy alone, and 1.75 and 2.37 for targeted therapy alone, respectively.</p><p><strong>Conclusion: </strong>Use of SACT at the EOL increased significantly over time, driven by increased use of immunotherapy. SACT use at the EOL, regardless of its type, was associated with high health services use and hospital death. Guidelines on the use of SACT at the EOL should include novel cancer treatments.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3279-3291"},"PeriodicalIF":41.9,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial. 不可切除胰腺癌诱导治疗后放化疗与化疗的获益:CONKO-007随机试验
IF 41.9 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-20 Epub Date: 2025-08-13 DOI: 10.1200/JCO-24-01502
Rainer Fietkau, Michael Ghadimi, Robert Grützmann, Uwe A Wittel, Lutz Jacobasch, Waldemar Uhl, Roland S Croner, Wolf Otto Bechstein, Ulf Peter Neumann, Dirk Waldschmidt, Stefan Boeck, Nicolas Moosmann, Anke C Reinacher-Schick, Henriette Golcher, Werner Adler, Sabine Semrau, Dorota Lubgan, Annett Kallies, Markus Hecht, Iris Tischoff, Andrea Tannapfel, Benjamin Frey, Helmut Oettle
{"title":"Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.","authors":"Rainer Fietkau, Michael Ghadimi, Robert Grützmann, Uwe A Wittel, Lutz Jacobasch, Waldemar Uhl, Roland S Croner, Wolf Otto Bechstein, Ulf Peter Neumann, Dirk Waldschmidt, Stefan Boeck, Nicolas Moosmann, Anke C Reinacher-Schick, Henriette Golcher, Werner Adler, Sabine Semrau, Dorota Lubgan, Annett Kallies, Markus Hecht, Iris Tischoff, Andrea Tannapfel, Benjamin Frey, Helmut Oettle","doi":"10.1200/JCO-24-01502","DOIUrl":"10.1200/JCO-24-01502","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the benefit, measured as complete removal of a tumor so that no tumor cells are detectable during histopathologic examination of the resection margin (R0 resection rate), of induction chemotherapy plus chemoradiotherapy (CRT) compared with chemotherapy alone for unresectable pancreatic tumors.</p><p><strong>Patients and methods: </strong>CONKO-007, an investigator-initiated open-label, multicentric, phase III randomized clinical trial, enrolled 525 patients with unresectable tumors, and 495 patients received induction chemotherapy (402 with fluorouracil, irinotecan, and oxaliplatin [FOLFIRINOX] and 93 with gemcitabine). Patients without progression after 3 months of induction chemotherapy (n = 336) were randomly assigned for continuation of the same chemotherapy (n = 167) or CRT (n = 169; 50.4Gy concurrently with gemcitabine). Resectability was centrally reassessed by a panel of surgeons. Surgery was recommended if possible. After an interim analysis, the primary end point was changed from overall survival (OS) to overall R0 resection rate because of slow recruitment. The median follow-up was 76 months. Important planned secondary end points were R0 resection rate in the surgically treated population and OS.</p><p><strong>Results: </strong>The primary end point (overall R0 resection rate) was not significantly different between treatment arms with 25% (43 of 169) in the CRT arm versus 18% in the chemotherapy arm (30 of 167; <i>P</i> = .113). Secondary end point analysis showed that surgery was performed equally often (<i>P</i> = .91); R0 resection rate in patients who underwent surgery was higher after CRT, 69.4% (43 of 62) compared with chemotherapy alone: 50.0% (30 of 60 patients, <i>P</i> = .04). Other parameters of resection (ratio of R0/R1/R2/no resection) also favored CRT (<i>P</i> = .02). No difference in OS was seen between treatment arms (hazard ratio [HR], 0.937 [95% CI, 0.747 to 1.174]; <i>P</i> = .57; randomly assigned intention-to-treat patients). Surgery was associated with longer OS (<i>P</i> < .001, HR, 0.525 [95% CI, 0.408 to 0.676]).</p><p><strong>Conclusion: </strong>Although not improving overall R0 resection rate or survival, CRT enables a R0 resection in surgically treated patients more often than chemotherapy alone.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3266-3278"},"PeriodicalIF":41.9,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144846652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial. 卡铂加入序贯紫杉-蒽环类新辅助化疗治疗三阴性乳腺癌:一项III期随机对照试验。
IF 45.3 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-20 DOI: 10.1200/jco-25-01023
Sudeep Gupta,Nita Nair,Rohini W Hawaldar,Shalaka Joshi,Seema Gulia,Tanuja Shet,Rajiv Sarin,Vani Parmar,Sangeeta Desai,Jaya Ghosh,Tabassum Wadasadawala,Vaibhav Vanmali,Tejal Panhale,Pallavi Parab,Asawari Patil,Garvit Chitkara,Sushmita Rath,Jyoti Bajpai,Rima Pathak,Palak Popat,Meenakshi Thakur,Rajendra A Badwe
{"title":"Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.","authors":"Sudeep Gupta,Nita Nair,Rohini W Hawaldar,Shalaka Joshi,Seema Gulia,Tanuja Shet,Rajiv Sarin,Vani Parmar,Sangeeta Desai,Jaya Ghosh,Tabassum Wadasadawala,Vaibhav Vanmali,Tejal Panhale,Pallavi Parab,Asawari Patil,Garvit Chitkara,Sushmita Rath,Jyoti Bajpai,Rima Pathak,Palak Popat,Meenakshi Thakur,Rajendra A Badwe","doi":"10.1200/jco-25-01023","DOIUrl":"https://doi.org/10.1200/jco-25-01023","url":null,"abstract":"PURPOSEWe evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC).METHODSIn this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m2) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study.RESULTSOf 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified P = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal P = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal P = .003; 5-year EFS 75.0% v 59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal P = .002; 5-year OS 78.2% v 64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal P = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal P = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities.CONCLUSIONCarboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"134 1","pages":"JCO2501023"},"PeriodicalIF":45.3,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating Racial and Ethnic Disparities Along the Care Cascade for Older Adults Newly Diagnosed With Metastatic Cancer. 调查新诊断为转移性癌症的老年人在护理级联中的种族和民族差异。
IF 41.9 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-20 Epub Date: 2025-08-28 DOI: 10.1200/JCO-25-01613
Jennifer L Lund, Vanessa E Slater, Allison Magnuson
{"title":"Investigating Racial and Ethnic Disparities Along the Care Cascade for Older Adults Newly Diagnosed With Metastatic Cancer.","authors":"Jennifer L Lund, Vanessa E Slater, Allison Magnuson","doi":"10.1200/JCO-25-01613","DOIUrl":"10.1200/JCO-25-01613","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3233-3236"},"PeriodicalIF":41.9,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. PASS-01:改良FOLFIRINOX与吉西他滨/ nab -紫杉醇及分子相关物治疗未治疗转移性胰腺癌的随机II期试验。
IF 41.9 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-20 Epub Date: 2025-09-24 DOI: 10.1200/JCO-25-02195
Jennifer J Knox, Grainne O'Kane, Daniel King, Daniel Laheru, Amber N Habowski, Kenneth Yu, Kimberly Perez, Andrew J Aguirre, Zachary Coyne, Harry Harvey, Ronan A McLaughlin, Raymond W Jang, Robert C Grant, Elena C Elimova, Daniel J Renouf, Sandra Fischer, Kai Duan, Stephanie Ramotar, Gun Ho Jang, Amy Zhang, Craig E Devoe, Harshabad Singh, Michael J Pishvaian, Fieke E M Froeling, Muhammad W Saif, Eileen M O'Reilly, Erica S Tsang, Brian M Wolpin, Julie M Wilson, Anna Dodd, Trevor J Pugh, Xiang Y Ye, Steven Gallinger, David A Tuveson, Faiyaz Notta, Elizabeth M Jaffee
{"title":"Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.","authors":"Jennifer J Knox, Grainne O'Kane, Daniel King, Daniel Laheru, Amber N Habowski, Kenneth Yu, Kimberly Perez, Andrew J Aguirre, Zachary Coyne, Harry Harvey, Ronan A McLaughlin, Raymond W Jang, Robert C Grant, Elena C Elimova, Daniel J Renouf, Sandra Fischer, Kai Duan, Stephanie Ramotar, Gun Ho Jang, Amy Zhang, Craig E Devoe, Harshabad Singh, Michael J Pishvaian, Fieke E M Froeling, Muhammad W Saif, Eileen M O'Reilly, Erica S Tsang, Brian M Wolpin, Julie M Wilson, Anna Dodd, Trevor J Pugh, Xiang Y Ye, Steven Gallinger, David A Tuveson, Faiyaz Notta, Elizabeth M Jaffee","doi":"10.1200/JCO-25-02195","DOIUrl":"10.1200/JCO-25-02195","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3325"},"PeriodicalIF":41.9,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer. 低雌激素受体乳腺癌优先治疗的再思考
IF 41.9 1区 医学
Journal of Clinical Oncology Pub Date : 2025-10-20 Epub Date: 2025-08-28 DOI: 10.1200/JCO-25-01176
Jincong Q Freeman, Rita Nanda, Frederick M Howard
{"title":"Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer.","authors":"Jincong Q Freeman, Rita Nanda, Frederick M Howard","doi":"10.1200/JCO-25-01176","DOIUrl":"10.1200/JCO-25-01176","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3322-3323"},"PeriodicalIF":41.9,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信